Table 2.

Summary of confirmed tumor response per RECIST v1.1 by investigator assessment.

	MK-4830 monotherapy	MK-4830 + pembrolizumab	Crossover to MK-4830 + pembrolizumab
Confirmed response, n (%)	n = 50	n = 34	n = 18
ORR	1 (2)a	8 (24)b	1 (6)c
CR	0	1 (3)	0
PR	1 (2)	7 (21)	1 (6)
SD	11 (22)	9 (26)	1 (6)
SD with PFS ≥6 months	5 (1)	6 (18)	0
PD	34 (68)	16 (47)	3 (17)
No RECIST assessmentd	4 (8)	1 (3)	13 (72)e

Abbreviations: CR, complete response; ORR, objective response rate; PFS, progression-free survival; PR, partial response; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1; SD, stable disease.

^aPatient had high-grade serous ovarian cancer.

^bPatients had microsatellite-high colorectal cancer (n = 2), gastric cancer (n = 2), head and neck squamous cell carcinoma (n = 1), Merkel cell carcinoma (n = 1), non–small cell lung cancer (n = 1), and papillary thyroid (n = 1).

^cPatient had microsatellite-high colorectal cancer.

^dIncludes patients who had the opportunity to have a postbaseline assessment based on the date of their first dose but did not have any postbaseline assessment by the data cutoff date.

^eEleven patients have been evaluated by immune Response Evaluation Criteria in Solid Tumors.